Table 2.

Major studies on alemtuzumab-based RIC SCT in lymphoproliferative diseases

Study	Diagnosis	Nr	Disease status	Age	Conditioning	Campath Dose	% Sib	TRM	Grade III – IV aGvHD	Extensive cGvHD	OS	DFS/PFS	DLI
[67]	NHL	88	88.6% S	48	Flu-Mel	100 mg	71%	23%	4.5%	4.5%	3y-55%	3y-50%	36/88
[68]	HG-NHL	48	83% S	46	Flu-Mel	20 – 100 mg	62%	29%	4.2%	13%	4y-47%	4y-48%	12/48
[77]	NHL, HL	67	66% S	54	Flu-Mel, Clo-Mel, Flu-Bu	100 mg	57%	30%	16.4% grade II – IV	7/67	3y-47%	3y-30%	3/67
[69]	MCL	70	81% S	48	Flu-Mel, BEAM, Flu-Bu	30 – 100 mg	60%	18%	10%	34%	5y-37%	5y-14%	27/70
[46]	CLL	41	83% S	54	Flu-Mel	40 – 100 mg	58%	26%	10%	4.9%	2y-51%	5y-45%	18/41
[70]	FL	82	90% S	45	Flu-Mel	20 – 100 mg	46%	12%	13% grade II – IV	20%	4y-76%	4y-76%	41/82
[79]	FL	44	90.9% S	48	BEAM	50 – 100 mg	64%	20%	No grade III – IV	6.8%	3y-69%	3y-58%	13/44
[78]	NHL, CLL, HL	65	20% CR	46	BEAM	50 – 100 mg	87%	13%	No grade III – IV	No extensive	3y-63%	3y-54%	17/65
[73]	HL	36	55.5% S	36	Flu-Mel	50 – 100 mg	100%	7%	No grade III – IV	2/36	4y-62%	4y-39%	19/36

Age: median age, aGvHD: cumulative incidence of grade III-IV acute graft-versus-host disease, BEAM: bis-chloroethylnitrosourea, Etoposide, Ara-C, Melphalan, Bu: busulfan, Camp: campath/alemtuzumab, Camp dose: cumulative dose of alemtuzumab, cGvHD: cumulative incidence of extensive chronic graft-versus-host disease, CLL: chronic lymphocytic leukemia, CR: complete remission, DFS: disease-free survival, Disease Status: disease status at the time of transplantation, DLI: donor lymphocyte infusion given for relapse or mixed chimerism, FL: follicular lymphoma, Flu: Fludarabine, HG-NHL: High-grade non-Hodgkin’s lymphoma, HL: Hodgkin’s lymphoma, MCL: mantle cell lymphoma, Mel: melphalan, NHL: non-Hodgkin’s lymphoma, Nr: numbers of patients, OS: overall survival, PFS: progression-free survival, RIC: reduced-intensity conditioning, S: chemosensitive disease, SCT: allogeneic stem cell transplantation, % Sib: proportion of sibling donor, TRM: treatment-related mortality 1 year after transplantation